Acquisitions11 Sept 2025, 02:02 am
Dr. Reddy’s Laboratories Acquires STUGERON® Portfolio from Johnson & Johnson for $50.5 Million
AI Summary
Dr. Reddy’s Laboratories Ltd. has entered into a definitive agreement with Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, to acquire the STUGERON® brand, including its leading local brands Stugeron® FORTE and Stugeron® PLUS, and related assets across 18 markets in the Asia-Pacific and Europe, Middle East, and Africa regions. The acquisition, valued at $50.5 million, strengthens Dr. Reddy’s Central Nervous System (CNS) Portfolio in India and Emerging Markets through its foray into the anti-vertigo segment. The operations will be gradually transitioned to ensure smooth integration of the business.
Key Highlights
- Dr. Reddy’s has acquired the STUGERON® portfolio from Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, for $50.5 million.
- The acquisition includes the STUGERON® brand, Stugeron® FORTE, and Stugeron® PLUS, as well as related assets across 18 markets in the Asia-Pacific and Europe, Middle East, and Africa regions.
- India and Vietnam are the key markets for this acquisition.
- This acquisition strengthens Dr. Reddy’s Central Nervous System (CNS) Portfolio in India and Emerging Markets.
- The operations will be gradually transitioned to ensure smooth integration of the business.